Filing summary
Entity and period: The supplied metadata identifies Gyre Therapeutics, Inc., but the filing is Catalyst Biosciences, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2022. The figures and disclosures below relate to Catalyst Biosciences, not Gyre Therapeutics.
Business context and strategic changes
Catalyst was a protease-engineering biopharmaceutical company. It ceased research and development activities in March 2022 and, by the end of the second quarter, had ceased all R&D. In May, Vertex acquired Catalyst’s complement portfolio and related intellectual property. Remaining coagulation assets—MarzAA, DalcA and CB 2679d-GT—were available for partnering. The company said it was exploring strategic alternatives and intended to distribute available cash after paying or reserving for obligations.
Financial performance and liquidity
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Collaboration revenue | $0 | $0.8 million |
| Research and development expense | $1.9 million | $11.6 million |
| General and administrative expense | $3.8 million | $8.8 million |
| Net income | $51.6 million | $37.1 million |
| Net income per share, diluted | $1.64 | $1.18 |
Net income primarily reflects a $57.2 million net gain on asset disposals, principally the Vertex transaction; it should not be viewed as recurring operating profitability. The filing does not provide a meaningful operating margin measure for this transition period.
- Cash and liquidity: Cash and cash equivalents were $75.4 million at June 30, 2022, versus $44.3 million at December 31, 2021. Current assets were $81.3 million and current liabilities were $4.3 million. Management believed available cash would fund requirements for at least 12 months from the filing date.
- Cash flows, six months: Operating activities used $24.3 million; investing activities provided $55.4 million, including $55.0 million received from Vertex; financing activities provided $0.02 million. Cash increased by $31.0 million.
- Debt: The balance sheet reports no borrowings. Operating lease liabilities totaled $1.4 million.
- Vertex sale: Consideration was $60.0 million: $55.0 million received at closing and $5.0 million held back for one year, subject to post-closing indemnification obligations. The holdback was recorded in receivables.
Changes versus the prior comparable period
- Second-quarter collaboration revenue fell from $1.1 million in 2021 to zero, following termination of the Biogen agreement, effective May 2022. First-half revenue declined 69%, from $2.6 million to $0.8 million.
- R&D expense decreased 88% in the quarter and 64% in the first half versus 2021, reflecting program wind-downs, workforce reductions and cessation of R&D.
- Net results shifted from losses of $19.9 million for the quarter and $42.4 million for the first half of 2021 to profits in 2022, largely because of the Vertex asset-sale gain.
- Operating cash use declined from $44.5 million in the first half of 2021 to $24.3 million in the first half of 2022. The 2021 period included $49.3 million of net public-offering proceeds; 2022 financing cash flow was negligible.
Outlook, risks and unusual items
- Management said it may distribute up to $65.0 million to stockholders in one or more distributions, but timing and amount were uncertain. Distribution capacity depends on litigation, operating and wind-down costs, taxes, other liabilities and receipt of some or all of the Vertex holdback.
- A Delaware Chancery Court lawsuit filed by stockholders alleges violations related to the Vertex sale and disclosure. Catalyst said it believes the claims lack merit; plaintiffs seek injunctive and declaratory relief and unspecified damages. The company could not estimate any potential loss.
- The Biogen agreement ended in May. A June settlement included forgiveness of approximately $0.6 million of receivables and a $10,000 cash payment, with a reported $0.6 million settlement expense.
- The company reported an unremediated material weakness in internal control over financial reporting concerning review and accounting treatment of certain employee retention bonuses. Disclosure controls were assessed as ineffective; remediation actions were underway but required sustained validation and testing.
- COVID-19 could disrupt the company’s ability to out-license remaining assets. The company also noted that future financing, if needed, might not be available on acceptable terms.
Important facts for investors to verify
- Confirm the entity mismatch: this filing is for Catalyst Biosciences, not Gyre Therapeutics.
- Track the $5.0 million Vertex holdback and whether post-closing conditions permit its release.
- Monitor the Delaware litigation, related expenses or liabilities, and the resulting timing and amount of any stockholder distribution.
- Assess cash burn and wind-down obligations against management’s stated 12-month liquidity estimate.
- Check progress in remediating and validating controls after the reported material weakness.
- Verify the status and potential monetization or partnering of the remaining coagulation assets.